Journal of Immunology Research

Antiphospholipid Syndrome and Antibodies


Publishing date
15 Aug 2014
Status
Published
Submission deadline
28 Mar 2014

1Centro Médico do Hospital Aliança, Salvador, BA, Brazil

2Faculdade de Ciências Medicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

3Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel


Antiphospholipid Syndrome and Antibodies

Description

Antiphospholipid syndrome is an acquired thrombophilia characterized by venous or artery thrombosis accompanied by or not accompanied by thrombocytopenia in the presence of antiphospholipid antibodies.

Nowadays, several scientists have tried to understand how and why the anti-phospholipid antibodies are linked to thrombotic events and even other nonvascular conditions. The knowledge of these conditions has led to the development of animal models, better knowledge of pathophysiology and new tools for diagnosis, and therapy of antiphospholipid syndrome. In addition, interest on cardiovascular manifestations, livedo reticularis, atherosclerosis, valvulopathy, and neurological and obstetric features is growing in these fields.

We are inviting investigators to submit their scientific papers, including original reviews, focused on aspects related to antiphospholipid syndrome and antibodies in humans or also in animal models. Potential topics include, but are not limited to:

  • Recent developments in pathophysiology of antiphospholipid syndrome/antibodies
  • Experimental studies on antiphospholipid syndrome/antibodies
  • Clinical vascular manifestations of antiphospholipid syndrome
  • Obstetric features in antiphospholipid syndrome
  • Treatment of vascular manifestations of antiphospholipid syndrome
  • Obstetric treatment of antiphospholipid syndrome
  • Cardiovascular manifestations of antiphospholipid syndrome
  • Atherosclerosis and antiphospholipid syndrome/antibodies
  • Neurological features and antiphospholipid syndrome/antibodies

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/cdi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/cdi/asas/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 942869
  • - Editorial

Antiphospholipid Syndrome and Antibodies

Jozélio Freire de Carvalho | Roger Abramino Levy | Yehuda Shoenfeld
  • Special Issue
  • - Volume 2014
  • - Article ID 672603
  • - Review Article

Clinical, Laboratory, and Therapeutic Analyses of 21 Patients with Neonatal Thrombosis and Antiphospholipid Antibodies: A Literature Review

Marcus Vinicius da Costa Peixoto | Jozélio Freire de Carvalho | Carlos Ewerton Maia Rodrigues
  • Special Issue
  • - Volume 2014
  • - Article ID 621270
  • - Review Article

Cardiovascular Risk Factors in the Antiphospholipid Syndrome

Felipe Freire da Silva | Roger Abramino Levy | Jozélio Freire de Carvalho
  • Special Issue
  • - Volume 2014
  • - Article ID 614591
  • - Review Article

Rheumatic Fever Associated with Antiphospholipid Syndrome: Systematic Review

Felipe da Silva | Jozélio de Carvalho
  • Special Issue
  • - Volume 2014
  • - Article ID 641962
  • - Clinical Study

Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease

Manuel Serrano | Jose Angel Martínez-Flores | ... | Antonio Serrano
  • Special Issue
  • - Volume 2014
  • - Article ID 239398
  • - Review Article

Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage

M. Carecchio | R. Cantello | C. Comi
  • Special Issue
  • - Volume 2014
  • - Article ID 195687
  • - Research Article

Optimization of Unnicked β2-Glycoprotein I and High Avidity Anti-β2-Glycoprotein I Antibodies Isolation

Andrej Artenjak | Adrijana Leonardi | ... | Saša Čučnik
Journal of Immunology Research
 Journal metrics
Acceptance rate40%
Submission to final decision61 days
Acceptance to publication33 days
CiteScore5.100
Impact Factor3.327
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.